Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open-Label Rollover Study of Levosimendan in Patients With Pulmonary Hypertension With Heart Failure and Preserved Left Ventricular Ejection Fraction (PH-HFpEF)

NCT03624010 is registered in ClinicalTrials.gov with Tenax Therapeutics, Inc. as lead sponsor.

NCT NCT03624010
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03624010 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open-Label Rollover Study of Levosimendan in Patients With Pulmonary Hypertension With Heart Failure and Preserved Left Ventricular Ejection Fraction (PH-HFpEF)
Lead sponsor
Tenax Therapeutics, Inc.
Phase
Phase 2
Overall status
Completed
Start date
April 9, 2019
Completion date
April 25, 2023
Enrollment
35 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

heart failure with normal ejection fraction, hypertension pulmonary secondary heart failure, right sided heart failure with normal ejection fraction